Papyrus Therapeutics
Board of Directors

Beth Altman
Chair of the Audit Committee
- 27+ years of experience in finance, management, business, accounting and internal controls
- Former managing partner at KPMG LLP San Diego
- Former KPMG LLP audit partner serving early-stage start-ups through complex public global corporations
- Advisor to companies on capital raises, initial public offerings, M&A and corporate governance matters

Marc Beer
Chairman
- • 30+ years development and commercialization experience
- Executive Chairman of BioTE Medical Inc
- Founder of Renovia Inc
- Former CEO of Aegerion Pharmaceuticals Inc (AEGR)
- Founder of Viacell Inc (VIAC) which got sold to Perkin Elmer (PKI) Inc Beecham

Paul Blake, FRCP
Founder & CEO
- 30+ years management and drug development experience
- Numerous NDA/sNDA/MAA approvals, including three entirely novel indications
- Former Chief Development Officer at Oxford Biomedica
- Former Executive VP of Worldwide Medical and Regulatory Operations at Cephalon
- Former Chief Medical Officer and Senior VP of Clinical R&D at SmithKline Beecham

Hani Gabra, PhD FRCP
Founder & CSO
- Internationally-recognized translational medical oncologist and gynecologic cancer expert with 30+ years of academic experience
- Professor Emeritus in Medical Oncology at Imperial College London
- Visiting Professor at the Center for Cancer Biomarkers at University of Bergen
- Former VP in early clinical development at Astra Zeneca
- Former CMO and head of clinical development at BerGenBio AS

Jim Lorens, PhD
Chair, Scientific Advisory Board
- 35+ years academic research and biotech industry experience across the US and Europe
- Head of Oncology and Founding Scientist at Rigel Pharmaceuticals Inc (RIGL)
- Founder of BerGenBio AS
- Professor in the Department of Biomedicine at the University of Bergen Faculty of Medicine
- Developed the first AXL targeting agent into the clinic